nach oben

Archives of Dermatological Research

Erschienen in:

01.06.2004 | Original Paper

Serum matrix metalloproteinase-3 in systemic sclerosis

verfasst von: Masatoshi Jinnin, Hironobu Ihn, Yoshihide Asano, Kenichi Yamane, Norihito Yazawa, Kunihiko Tamaki

Erschienen in: Archives of Dermatological Research | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

To determine the serum levels of matrix metalloproteinase-3 (MMP-3) in patients with systemic sclerosis (SSc) and investigate their clinical significance in this disease, serum samples from 83 patients with SSc and 30 healthy volunteers were examined by a specific enzyme-linked immunosorbent assay (ELISA). There was no significant difference in serum levels of MMP-3 between SSc patients and healthy controls. However, in female patients, there was a significant difference in serum MMP-3 levels between patients subsequently developing accompanying rheumatoid arthritis (RA) and those not developing RA, and patients with increased levels of MMP-3 were more likely to develop RA than those with normal MMP-3 levels. Additionally, arthralgia, elevated CRP, and elevated rheumatoid factor were seen significantly more frequently in patients with increased MMP-3 levels than in those with normal MMP-3 levels. These results suggest that increased serum MMP-3 is a marker for developing RA in SSc patients. SSc patients with increased serum MMP-3 levels need to be followed up carefully because of the risk of developing overlapping RA.

Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130–140PubMed

LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51:3412–3419

Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD (1995) Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 270:3423–3428CrossRefPubMed

Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K (1995) Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 33:973–978PubMed

Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kahari VM (1998) Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 110:416–421CrossRefPubMed

Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y (1994) Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 103:359–363

Murawaki Y, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 281:109–120CrossRefPubMed

Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969–975PubMed

Wu JJ, Lark MW, Chun LE, Eyre DR (1991) Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem 266:5625–5628PubMed

10.

Obata K, Iwata K, Okada Y, Kohrin Y, Ohuchi E, Yoshida S, Shinmei M, Hayakawa T (1992) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta 211:59–72CrossRefPubMed

11.

Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ (1987) Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 248:265–268PubMed

12.

He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI (1989) Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 86:2632–2636PubMed

13.

Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581–3584PubMed

14.

Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H (1989) Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis 48:645–653PubMed

15.

Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228–233PubMed

16.

Subcommittee for Scleroderma Criteria of the ARA Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–589PubMed

17.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–206PubMed

18.

Ihn H, Sato S, Fujimoto M, Kikuchi K, Igarashi A, Soma Y, Tamaki K, Takehara K (1996) Measurement of anticardiolipin antibodies by ELISA using β₂-glycoprotein I (β₂-GPI) in systemic sclerosis. Clin Exp Immunol 37:1188–1192

19.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed

20.

Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, Takehara K (1992) Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 284:391–395PubMed

21.

Otsuji S, Shibata H, Umeda M (1982) Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 28:2121–2124PubMed

22.

Ailus K, Melamies L, Tuomi T, Palosuo T, Aho K (1991) Measuring rheumatoid factor in nonrheumatoid subjects: immunoturbidimetric assay, latex slide test, and enzyme- linked immunosorbent assay compared. Clin Chem 37:1766–1769PubMed

23.

Klein F, Janssens MB (1987) Standardization of serological tests for rheumatoid factor measurement. Ann Rheum Dis 46:674–680PubMed

24.

Gendi N, Gordon T, Tanner SB, Black CM (1992) The evolution of a case of overlap syndrome with systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus. Br J Rheumatol 31:783–786PubMed

25.

Gendi NS, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM (1995) HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 38:259–266PubMed

26.

Horiki T, Moriuchi J, Takaya M, Uchiyama M, Hoshina Y, Inada K, Inoko H, Tsuji K, Ichikawa Y (1996) The coexistence of systemic sclerosis and rheumatoid arthritis in five patients: clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 39:152–156PubMed

27.

Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smolen JS (1998) The concurrence of rheumatoid arthritis and limited systemic sclerosis. Arthritis Rheum 41:1938–1945CrossRefPubMed

28.

Rodnan GP (1962) The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 56:422–439PubMed

29.

Tuffanelli DL, Winkelmann RK (1961) Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 84:359–371PubMed

30.

Aho K, Palosuo T, Knekt P, Alha P, Aromaa A, Heliövaara M (2000) Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol 27:1136–1138PubMed

31.

Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I (2002) The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 20:221–224PubMed

32.

Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMed

33.

Panat MJ, Williams AL, O’sullivan MM, Lewis PA, Coles EC, Jessop JD (2000) Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 43:1473–1477CrossRefPubMed

34.

van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, Limburg PC (1994) Interrelationships of outcome measures and process variables in early rheumatoid arthritis—a comparison of radiological damage, physical disability, joint counts and acute phase reactions. J Rheumatol 21:425–429PubMed

35.

Otterness IG (1994) The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 24:91–104PubMed

36.

Williams RC Jr (1983) Symposium on the immunodiagnosis of rheumatic and related disease. Part II. Rheumatoid factors. Hum Pathol 14:386–391PubMed

37.

Young A, van der Heijde D (1997) Can we predict aggressive disease? Baillieres Clin Rheumatol 11:27–48PubMed

38.

Borghaei RC, Rawlings PL Jr, Mochan E (1998) Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum 41:1398–1406CrossRefPubMed

39.

Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP (2000) The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 43:270–274

40.

Morin I, Li WQ, Su S, Ahmad M, Zafarullah M (1999) Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. J Pharmacol Exp Ther 289:1634–1640PubMed

Titel: Serum matrix metalloproteinase-3 in systemic sclerosis
verfasst von: Masatoshi Jinnin
Hironobu Ihn
Yoshihide Asano
Kenichi Yamane
Norihito Yazawa
Kunihiko Tamaki
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 1/2004
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-004-0468-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2004

Histochemistry of complex carbohydrates in the ceruminous glands of the goat

A novel missense mutation of the ATP2A2 gene in a Chinese family with Darier’s disease

Hanan Polansky: Microcompetition with foreign DNA and the origin of chronic disease

Meeting Calender 06/2004

Calcium entry into keratinocytes induces exocytosis of lysosomes